Looking to publish in Clinical Lung Cancer? Livewrite integrates seamlessly with Word to help you write, edit, and format faster.
Existing customer loginClinical Lung Cancer is a peer-reviewed bimonthly journal that publishes original articles on clinical and translational research of lung cancer, with emphasis on detection, diagnosis, prevention, and treatment, including clinical research and mechanistic approaches, drug sensitivity and resistance, gene and antisense therapy, pathology, markers and prognostic indicators, chemoprevention strategies, multimodality therapy, and integration of various approaches.
Looking to publish in Clinical Lung Cancer? Livewrite integrates seamlessly with Word to help you write, edit, and format faster.
Existing customer loginSubmission Instructions
Clinical Lung Cancer accepts the following article types. Click on an article type to view submission instructions.
Reviews
Original Studies
Systematic Reviews
Meta-Analyses
Targeted Mini-Reviews
Case Reports
Brief Reports
Letters To The Editor
Recent Publications
Neoadjuvant Chemoimmunotherapy in Resectable NSCLC With PD-L1 Expression < 1%: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials
Isadora Mamede, Skyler Taylor, Rafael Lara Nohmi, Israt Jahan Riya, Ifrat Jahan Piya, Antonious Hazim, Vinicius Ernani
Trastuzumab Deruxtecan in Patients From China With Pretreated HER2-Mutant Non-Small Cell Lung Cancer: Final Analysis of the Phase 2, Single-Arm DESTINY-Lung05 Trial
Ying Liu, Dairong Li, Lin Wu, Xingya Li, Yun Fan, Mingjun Zhang, Jun Guo, Yu Yao, Jian Fang, Ke-Jing Tang, Feng Luo, Yan Yu, Xuhong Min, Zizheng Song, Jie Hu, Rui Ma, Huaping Yang, Yongqian Shu, Ruilian Xu, Buhai Wang, Xiaorong Dong, Yunru Chen, Rui Mao, Victor Zhang, Yong Fang
Outcomes of platinum plus pemetrexed and treatment patterns following first-line nivolumab and ipilimumab in pleural mesothelioma: real-world results from the German MesoNet study
Rajiv Shah, Eva L. Buchmeier, Hans-Georg Kopp, Frank Griesinger, Martin Reck, Daniel C. Christoph, Jonas Kuon, Nikolaj Frost, Christian Grohé, Martin Faehling, Felix C. Saalfeld, Petra Hoffknecht, Jingting Luan, Julia Roeper, Paolo Chesi, Martin Kimmich, Till Olchers, Laura V Klotz, Inn Chung, Michael Thomas, Petros Christopoulos
Pretreatment SUVmax Stratifies the Benefit of Consecutive Daily SBRT in Early-Stage Non-Small Cell Lung Cancer
Yupeng Di, Haifeng Pang, Xuan Wang, Lingling Meng
Complete spontaneous regression of lung adenocarcinoma with no residual malignancy after surgical resection: a case report
Anders Näslund, Hans Brunnström, Jesper Andreasson, Marija Karadzovska-Kotevska, Hamid Akbarshahi
Frequently asked questions
How long does it take to publish?
13 days from submission to first decision; 67 days from submission to decision after review; 110 days from submission to acceptance; 5 days from acceptance to online publication.
Reformat to Clinical Lung Cancer using Livewrite PremiumWhat are the publication costs?
Open access APC: USD 3330 excluding taxes for all articles. Subscription publication has no open access publication fee.
Reformat to Clinical Lung Cancer using Livewrite Premium